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Abstract
Purpose: Radiotherapy post-lumpectomy with two coplanar tangent beams is thestandard treatment for women with early stage breast cancer. Despite the use ofwedges as tissue compensators, the resultant plans often contains a significantdose gradient and 'hot spots' in excess of 15% or more of prescribed dose. Inrecent years a field-in-field (FIF) dose-compensation technique, which use twostandard tangent fields and one or two (rarely three) small beams within these,was developed. It allows to obtain a more uniform dose throughout the targetvolume in the majority of cases but not in all. This study presents our experience todevelop optimal intensity modulated radiation therapy (IMRT) techniques to beapplied clinically in those cases where the traditional technique with two tangentfields or its variant field in field (FIF) are unable to achieve a satisfactory planningtarget volumes (PTVs) coverage and dose objectives to the organs at risk (OARs).
Methods: We investigated two pure IMRT plans (named 3F-IMRT and 4F-IMRT)and a hybrid one (H-IMRT). Treatment plans were performed for 7 left-sided and 4right-sided breasts using simultaneously integrated boost (SIB) planned techniquewith inverse optimization. Results were compared with those obtained with FIFtechnique. Dose prescribed was 45 Gy/20 fractions to the breast and 50 Gy /20fractions to the lumpectomy cavity delivered in 5 fr/week. Dose–volumehistograms were generated and parameters as target dose coverage, conformityand homogeneity as well as OARs dose distribution were analyzed. Finally thesecondary cancer risk to contralateral breast due to radiation was evaluated as afurther parameter for the choice of the optimal plan. Results: Compared to the FIF,the three IMRT plans provided the same target coverage and a better doseconformation, but a worst dose homogeneity of the boost target. The volume of theOARs, receiving higher doses than 15 Gy was reduced but was increased thevolume receiving low doses. This causes the increase of the risk of radiationinduced cancer, especially for the contralateral breast. For this organ, the highestvalue of the excess absolute risk (EAR) was associated to the 4F-IMRT, while thelower, to the FIF. Conclusion: The intensity-modulated radiation therapytechniques 5F-IMRT and 4F-IMRT were the best to be applied clinically in thosecases, where the traditional technique of irradiation of the breast is unable toachieve the PTVs coverage and dose objectives to the OARs. However, all the IMRTtechniques showed an increased volume of healthy tissues receiving low doses, sothey should not be used in extensive manner and in particular should be avoided inthe cases of young women due to the excess of risk to develop a secondary cancer.
Keywords: Breast cancer, Radiotherapy, IMRT, Treatment planning, Dosimetry,Contralateral breast dose, Second cancer risk.
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1. IntroductionBreast cancer is the most common malignancy amongwomen.1,2 The standard of care is the conserving surgeryor mastectomy followed by adjuvant radiotherapy.Various studies have shown that radiation treatmentsignificantly improves local control and long-termsurvival,3,4 an additional boost to the tumor bed furtherreduces local recurrences.5,6 Conventionally, breastradiation therapy of 50 Gy in 25 fractions is prescribed,with up to an additional 10 Gy in 5 fractions to thetumor bed. The boost is usually delivered after the lastfraction of the whole breast treatment (sequentialboost), but it is also widely used the irradiationtechnique in which boost is given in the same fractionjust after the whole breast treatment (concomitantboost) reducing the total treatment period. When IMRTcame, the SIB technique was introduced where the twotarget volumes (whole breast and lumpectomy cavity)were treated simultaneously with different dose levels.Anatomically, the breast presents a very challenginggeometry. Doses to the lungs and heart must be kept lowto avoid long-term complications, because most patientshave a long life expectancy, as well as the dose to thecontra-lateral breast, out of concern for possible inducedsecond malignancies.Three-dimensional conformal radiation therapy(3DCRT) with 2 opposed tangent fields is the standardtreatment technique with the aim to achieve suitabletarget volumes coverage and to spare the neighboringhealthy tissue. Wedges are frequently employed tocompensate for different thicknesses across the breast.The efficacy of this treatment method has been provedin many clinical studies, which report positive results interms of local control rate.However, the traditional method, in some cases as largesize breast, induces significant dose inhomogeneity aslarge as 15–20% in the superior and inferior regions ofthe breast, making relatively large hot regions andexcessive exposure of normal tissue. In order to treatsuch cases, since 2006, we replaced the standardwedged tangential fields with FIF technique. FIF is asimple form of direct IMRT in which one or two smallbeams manually defined by the planner are addedwithin the two standard tangent fields, shape and weightare optimized by planner using the multi-leaf collimatorto create the best dose distribution.Sometimes, however, also the FIF solution is notsufficient for patients with particular anatomicalconformations. Thus, we started with a study whichaimed to find an IMRT-SIB step and shoot technique,which allowed us to obtain better results respect to FIFtreatment as: 1) a better dose coverage andconformation of the targets; 2) a lower dose to the OARs;
3) a time delivering dose comparable to the FIFtechnique.In this work we report our investigation of three IMRTtechniques, the results are compared with FIFconcomitant boost and the risk of secondary tumor tocontralateral breast is calculated.
2. Methods and Materials
2.1. Patients selectionIn our hospital about 500 plans for the breast cancer areperformed every year. In most of these the FIF techniqueis performed because it provides satisfactory doseconformation and uniformity of the targets and therespect of the OARs dose constraints. IMRT isimplemented for that cases in which FIF technique is notenough to obtain an optimal dose distributions to thebreast: as bottle breast (pectus excavatum) or particularanatomic conformation that implies an excessiveirradiation of lung or heart. Mandatory for patientinclusion in IMRT is their ability to maintain the positionduring the treatment, which can take up to 20 min.In the present study, we have selected 11 breast cancercases post lumpectomy (7 left sides and 4 right sides) forwhich the standard technique did not reach satisfactoryresults. The tumor grading was G1-G3 (1 G1, 7 G2 and 3G3), and the patient median age was 52 (range 32-73).In order to find a good IMRT technique to apply, fourdifferent models of planning was performed for eachpatient and dose distribution obtained was comparedanalyzing the difference in PTV dose uniformity andcoverage, exposure of organs at risk and risk of secondcancer induction to contralateral breast.
2.2. CT scanningComputed tomography (CT) scans of patients wereobtained using a Philips Brilliance CT (Philips MedicalSystems, Andover, MA, USA) with 5-mm slice thickness.Patients were supine on a carbon fiber (breast board) inthe treatment position with the ipsilateral armpositioned above the head. The clinical breast bordersand lumpectomy scar were marked with radiopaquecatheters. CT axial images were acquired for the areaextending from 1cm above the head of the clavicle toincluding the entire bilateral lungs in free breathing inthe lower part.
2.3. Delineation of target volumes and OARsPTVs and OARs, defined as recommended by ICRUreports,7,8 were delineated by expert radiationoncologist. Whole breast tissue was delimited: medially,from 2 cm to the edge of the sternum, laterally, to themidaxillary line; superiorly at the inferior edge of themedial head of the clavicle and inferiorly at the
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inframammary fold. The posterior border was thejunction with the chest wall or pectoralis major muscle.The breast planning target volume was obtained fromthe breast tissue plus a margin of 0.5 cm, then retractedfrom the skin by 5 mm and limited posteriorly to nodeeper than the posterior surface of the ribs (to excludethe ipsilateral lung). The PTV boost was the surgical bed,based on postsurgical architectural distortion andsurgical clips, correlated with the surgical scar,operative, and pathology reports.9,10In this study the volume of PTV boost was called PTV2,while the whole breast volume with subtracted PTV2was called PTV1. The organs selected as OARs includinglungs, contralateral breast, heart (from its apex to thejunction of the great vessels with the myocardium) andleft anterior descending (LAD) coronary artery, werecontoured.An additional structure specified as “healthy tissue” wasdefined with the aim of evaluating the dose to all thehealthy tissue, it was obtained by subtracting to thebody contour the whole volume PTV1 + PTV2.
2.4. Evaluation of respiratory movementsAccurate and reproducible patient setup is aprerequisite to correctly deliver fractionatedradiotherapy and can be of great relevance especiallywhen using highly conformal techniques as IMRT. Forthis reason, in the preliminary phase of clinicalimplementation, a study of chest’s movement for therespiratory excursion was done using the optical surfacetracking system Align RT 5.0 by Vision RTLtd (DoveHouse Arcania Avenue, London UK). Align RT is a videobased three-dimensional surface imaging system that isused to image the skin surface of patients before andduring radiotherapy treatment. In order to minimize thesetup errors that can result from respiratory motion, thesystem acquire real time imaging of patient. Thefollowing maximum movements of isocenter positionand its projections on the patients’ skin were measured:±2 mm in the posterior-anterior direction; ±1 mm incranio-caudal direction; ±1 mm in latero-lateraldirection. In order to evaluate how respiratoryexcursion influence the dose-volume histogram (DVH)all the combinations of maximum isocentre’s shift in x, y,z directions due to the breath were simulated and dose’sdistribution recalculated. The obtained results showedthat the volume covered by the isodose 95% rangedbetween 99% (no isocenter shift) and 97.5% for thetargets while as regards all the OARs the dose variationwas between 0% and ± 2.5%. In all cases the doseconstraints were always respected. To accommodaterespiratory motion, in all the IMRT plans a skin marginin air was given to the fields enlarging at least 1.5 cm outof the body contour.
2.5. Dose prescription and constraintsThe prescribed dose for all patients was 45 Gy/20fr(2.25 Gy/fr) to the PTV1 and 50 Gy/20fr (0.25 Gy/fr) tothe PTV2 through concomitant boost technique for FIFand SIB for IMRT step and shoot plans. In Table 1 doseconstraints for breast/boost target volumes and OARsare reported. Plans were normalized so that 95% of theprescription dose was delivered at least 95% of thetarget volumes.
Table 1: Dose constraints for breast/boost target volumesand organs at risk for a prescribed dose of 45 Gy to thePTV1 and 50 Gy to the PTV2Tissue/Organ Objective/constraintsPTV1/PTV2 D95% ≥ 95%Ipsilateral lung V20% ≤ 20%Heart V30% ≤ 5%V20% ≤ 10%V10% ≤ 15%V5% ≤ 20%Contralateral breast V5% < 15%Dx%=percentage of prescribed dose given to x% of volumetarget . Vx%=percentage of the volume receiving x% ormore of prescription dose.
2.6. Planning techniqueFour techniques have been investigated in order todetermine the optimal one:
 field-in-field technique (it was the reference withwhich to compare the others);
 hybrid inverse planning (H-IMRT);
 IMRT inverse planning with 4 fields, 2 medial and2 lateral (4F-IMRT);
 IMRT inverse planning with 5 fields, 2 medial, 2laterals and 1 anterior (5F-IMRT).All plans were generated using Oncentra MasterplanV.4.3 TPS. Beam gantry angles were chosen mainly onthe basis of the internal and external anatomy ofpatients by using 6 MV photon beams delivered by anElekta Precise linac. Collapsed cone convolutionalgorithm was used for the dose calculation. For all theIMRT Inverse planning, step and shoot technique wasapplied.The FIF technique is a 3DCRT technique but can be seenalso as a very simple IMRT forward planning. Since 2006it is performed in our hospital using two standardtangent field and one or two small beams within these(Figure 2-a1). These subfields were designed to reducehot volumes in the breast and the dose to the OARs dueto the large tangent fields. About 90% of the prescribeddose to the breast was delivered by the primary fieldswhile the remaining 10% by the FIF (Figure a1).Additional 5 Gy was given to the lumpectomy cavity byconcomitant boost (Figure 2-a2). The H-IMRT combinedtwo open standard tangent fields directly optimized,weighted 20%, and  the same beams plus two
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additional fields at optimal angles, to cover the PTVBoost inversely optimized, weighted 80%10 (Figure 2-b).The 4F-IMRT used the same beams of the H-IMRT butentirely inversely optimized (Figure 2-b). Lastly, the5F-IMRT was obtained adding to the 4F-IMRT, anoblique anterior beam with a low weight (Figure 2-c). As
regards the treatment delivery time of the IMRTtechniques, it was not too longer than the field-in-field(20 min vs. 15min), but, the pre-treatment steps(contouring of organs, planning and pre-treatmentverification) were time expensive for physicist andphysician staff.
Figure 1: Examples of patients candidate for IMRT. On the left, a case of sternum re-entered, on the right a particularanatomic conformation with a large lung volume included in the tangential fields.
Figure 2: Beam orientation. a1) tangent beams of the FIF technique; a2) simultaneous boost of FIF; b) H-IMRT and 4F-IMRT;c) 5F-IMRT.
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2.7. Dose evaluation parametersTo evaluate the dose distribution to PTVs and OARs, thedose information was collected from DVHs. For thetarget dose coverage, conformity and homogeneityanalysis, four indices were calculated for each planassuming as reference isodose the 95% of theprescribed dose.
Target Coverage (TC), calculated with the formula ofSalt-Lomax-Scheib:11-14
,  t RI
t
VTC V
where, Vt,RI is the volume covered by the referenceisodose 95% and Vt is the target volume, is used toevaluate the target coverage by the reference dose andranges between 0 and 1, where 1 is the ideal value.
Conformity Index (CI), defined as Lomax and Scheibsuggest11-14, by the ratio of the tissue volume covered bythe reference isodose Vt,RI (95%) and the volumeenclosed by the reference isodose VRI:
,t RI
RI
VCI V
is used to evaluate the conformity of the target by thereference dose; it can assume values between 0 and 1,where 1 is the best value (good conformation of targetand lower dose to nearest organs), whereas valuescloser to zero indicates total absence of conformity.
Conformation Number (CN) by Riet et al.13-14, is theproduct of the first two indexes and takes into accountboth the irradiation of the target volume and of healthytissue:
2
,( )t RI
RI t
VCN CI TC V V  
As TC and CI, CN can assume values between 0 and 1,where 1 is the ideal value (good conformity andcoverage of the target).
Homogeneity Index (HI), defined as the formularecommended in ICRU Report 83,8 but assuming asminimum PTV dose D95%:
2% 95%
50%
100D DHI D

HI assumes values ≥ 0 but, on the contrary of the otherindexes, values closer to zero indicates a greaterhomogeneity.
3. Results and Discussions
3.1. TargetThe obtained mean doses to PTV1 and PTV2,considering all the patients of the study, are showed inTable 2. The t-test was applied to determine thestatistical differences between the dose volume data forIMRT versus FIF plans. The p-value calculated is twotailed and p-values < 0.05 are considered significant.The average dose to the 100% of PTV1 in all the plansranges between 46.07 Gy (102.3%) for 5F-IMRT and47.33 Gy (105.1%) for FIF. The dose coverage, D95%, isabout 43.3 (96.2%) for 4F-IMRT and 5F-IMRT against44.3 (98.4) for FIF. The difference between D2% (nearmaximum dose8) of FIF and IMRT plans is notstatistically significant.The same parameters are shows for PTV2. Here, on thecontrary of PTV1, substantially no significant differencesresult between all values except in the case of the V100that has the minimum value with the 4F-IMRT.To have a visual immediate comparison between thedifferent techniques about the dose coverage,conformity and homogeneity of the targets for each plan,the indices TC, CI, CN and HI were calculated and resultsfor PTV1 and PTV2 showed in cumulative histograms ofFigure 3 and Figure 4.The ideal value for CI, TC and CN is 1 so, for the 11patients of this study, the best value obtainable incumulative histograms, or maximum total score is 11.For HI, instead, the best total score is 0.For PTV1 and PTV2 all the techniques have a goodcumulative target coverage TC (10.5 - 11.0), whereas thecumulative CI for FIF is significantly lower than in thethree IMRT. These results are confirmed looking thecumulative CN, here is evidenced the equivalence of thethree IMRT techniques for the PTV1, but not for thePTV2, where 5F-IMRT is better than 4F-IMRT and this,in turn, is better than H-IMRT. As regards thehomogeneity, we find the best value of cumulative HI inthe 4F and 5F-IMRT for PTV1 and in the FIF for PTV2.
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Table 1: Comparison of mean doses (Mean ± SD) to PTV1 (breast-boost) and PTV2 (boost) for FIF, H-IMRT, 4F-IMRTand 5F-IMRT planning techniques; prescription dose: 45 Gy to PTV1 and 50 Gy to PTV2.Target Parameter FIFmean ± SD H-IMRTmean ± SD 4F-IMRTmean ± SD 5F-IMRTmean ± SD
PTV1 Dmean (Gy) 47.33 ± 0.69 47.32 ± 2.73 46.31 ± 0.56† 46.07 ± 0.41†V100% (%) 87.90 ± 6.11 81.88 ± 7.95 77.24 ± 8.80† 72.84 ± 7.96†D95% (Gy) 44.33 ± 0.43 44.25 ± 2.60 43.25 ± 0.62† 43.33 ± 0.31†D2% (Gy) 51.55 ± 0.91 50.51 ± 2.73 49.03 ± 0.67 49.07 ± 0.65PTV2 Dmean (Gy) 51.13  0.64 52.09  2.60 50.37  1.48 51.47  0.73V100% (%) 79.41  11.48 81.90  8.84 62.43  19.61† 79.04  11.78D95% (%) 48.97  0.67 49.68  2.60 47.97  1.55 48.84  0.53D2% (Gy) 53.15  0.83 54.42  3.16 53.10  1.04 53.76  0.90SD = standard deviation; Dx%= lowest dose received by at least x% of the volume.Vx%=percentage of the volume receiving x% or more of prescription dose;
†= statistically significant difference with FIF technique (p < 0.05).
Figure 3: Comparison of PTV1 (breast-boost) cumulative index scoring for the four irradiation techniques.
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Figure 4: Comparison of PTV2 (boost) cumulative index scoring for the four irradiation techniques.
3.2. Organs at riskThe organs at risk data were analyzed according to planobjectives. Mean dose volume and standard deviationsfor the heart, LAD artery, lungs, contralateral breast andfor all healthy tissue body-(PTV1 + PTV2) are showed inTable 3. The dose constraints were respected for allplans.For the heart, when left breast irradiation is taken intoaccount, by analyzing the p-value, only V40Gy and V5Gyhave significant differences among the three IMRTplanning and FIF technique. As expected, the volume ofthe heart receiving high doses is lower for IMRTplanning compared to the FIF due to beam directions,whereas the opposite happens with low doses (Table 3).For the LAD artery, the dose does not presentstatistically significant difference between IMRT and FIF(p >0.05).In both lungs the 5F-IMRT plan exhibits the highestmean dose, however, in the ipsilateral, the three IMRTtechniques exhibit the V40Gy and V30Gy lowest than the FIFcase, while, V20Gy is substantially equivalent in all thefour techniques.
A particular organ at risk, for the second cancerinduction, is the contralateral (CTRL) breast. In Table 3we can see as the mean dose and the V5Gy volumes arelow in all the cases, respectively < 1Gy (2% of theprescribed dose) and < 0.3 Gy (0.6% of the prescribeddose). As is intuitive, the volume percentage ofcontralateral breast receiving 2 Gy (V2Gy) is lower usingthe FIF technique compared to IMRT cases, whereas thehighest mean dose is given by the 5F-IMRT.  In theremainder of this work, the risk of radiation-inducedcancer to this organ will be assessed.Regarding the dose distribution to healthy tissue(body-whole breast) significant differences amongdose-volume parameters of IMRT and FIF plans can beobserved. Figure 5 shows the curves obtained fittingwith a polynomial the data in Table 3 (volume versus thedose received at the healthy tissue). We can see as, in thelow dose range (less to about 15 Gy), the technique FIFgives less dose to healthy tissue than the three IMRTtechniques. Among these, the 5F-IMRT presents thehighest volume contoured by low dose (V5Gy= 24.21%).The situation is reversed for doses greater than about 15Gy, indeed, in this range the healthy tissue receives thehighest dose from the FIF plan.
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Table 2: Doses (mean ± SD) to organs at risk for FIF, H-IMRT, 4F-IMRT and 5F-IMRT planning techniques;prescription dose: 45Gy to PTV1 and 50 Gy to PTV2.
SD = standard deviation; Vx%=percentage of the volume receiving x% or more of prescription dose;Dx%=lowest dose received by at least x% of the volume.
†= statistically significant difference with FIF technique (p < 0.05).
Table 4: Organ Equivalent Dose (OED) Gy and Excess Absolute Risk (EAR) for contralateral breast.FIFmean ± SD Hybridmean ± SD 4F-IMRTmean ±  SD 5F-IMRTmean ± SDOED (Gy) 0.6±0.3 0.8±0.3 0.9±0.4 0.7±0.1EAR* 2.3±1.1 2.9±1.1 4.0±3.2 2.7±0.5*per 10.000 women-years at age of 70 years after exposure at the age of 50 years.
OAR Parameter FIFmean ± SD Hybridmean ± SD 4F-IMRTmean ± SD 5F-IMRTmean ± SD
HEART left breastirradiation
Dmean (Gy) 4.80 ± 2.08 4.51 ± 1.16 4.58 ± 1.02 5.28 ± 0.73V40Gy (%) 3.88 ± 2.57 2.41 ± 1.34† 1.16 ± 0.93† 1.18 ± 0.90†V30Gy (%) 6.44 ± 4.18 4.53 ± 2.34 3.70 ± 1.95 3.59 ± 2.12V20Gy (%) 7.97 ± 4.82 6.32 ± 2.95 5.66 ± 2.70 5.50 ± 2.87V10Gy(%) 10.06 ± 5.56 9.47 ± 3.69 9.37 ± 3.08 9.77 ± 2.21V5Gy (%) 13.60 ± 6.52 16.95 ± 5.36† 19.16 ± 3.52† 23.44 ± 5.84†LAD artery V20Gy (%) 53.31 ± 34.57 51.80 ± 34.62 42.10 ± 33.11 39.11 ± 33.39Dmax (Gy) 30.97 ± 16.43 27.09 ± 14.33 26.01 ± 15.22 24.17 ± 13.15
IPSL LUNG Dmean (Gy) 8.55 ± 8.43 8.78 ± 8.37 9.30 ± 8.72 11.13 ± 10.82†V40Gy (%) 8.06 ± 4.02 3.92 ± 2.60† 3.49 ± 2.39† 2.81 ± 1.60†V30Gy (%) 13.61 ± 5.12 10.92 ± 4.07 10.14 ± 3.69 10.32 ± 3.51†V20Gy (%) 16.41 ± 5.32 16.09 ± 5.22 15.81 ± 4.84 16.96 ± 4.08
CTRL LUNG Dmean (Gy) 0.37 ± 0.14 0.98 ± 1.84 0.43 ± 0.17 2.23 ± 1.25†V5Gy (%) 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.01 11.56 ± 19.58V2Gy (%) 0.21 ± 0.32 0.40 ± 0.64 0.37 ± 0.67 35.36 ± 21.37
CTRL BREAST Dmean (Gy) 0.55 ± 0.12 0.66 ± 0.13 0.58 ± 0.31 0.73 ± 0.14†V5Gy (%) 0.11 ± 0.23 0.11 ± 0.17 0.29 ± 0.49 0.20 ± 0.28V2Gy (%) 1.48 ± 1.33 2.43 ± 2.08 2.67 ± 3.06 2.71 ± 2.48D2% (Gy) 9.54 ± 11.15 5.70 ± 3.61 4.88 ± 3.38 5.35 ± 2.78
HEALTY TISSUE
Dmean (Gy) 4.21 ± 2.73 4.36 ± 2.67 4.33 ± 2.58 4.78 ± 0.84V50Gy (%) 0.21 ± 0.19 0.17 ± 0.48 0.02 ± 0.03† 0.02 ± 0.02†V45Gy (%) 1.90 ± 1.03 0.77 ± 0.90† 0.49 ± 0.29† 0.42 ± 0.30†V30Gy (%) 5.94 ± 1.93 5.03 ± 1.51 4.68 ± 1.11 4.54 ± 1.04†V20Gy (%) 6.96 ± 2.06 6.63 ± 1.92 6.44 ± 1.65 6.50 ± 1.50V15Gy (%) 7.58 ± 2.21 7.62 ± 2.33 7.56 ± 2.11 8.03 ± 1.82V10Gy (%) 8.38 ± 2.39 9.42 ± 3.19 9.81 ± 3.05 11.42 ± 2.91†V5Gy (%) 10.03 ± 2.73 14.91 ± 4.07† 15.73 ± 3.68† 24.21 ± 7.06†
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Figure 5: V% vs. dose for healthy tissue (body-whole breast) when 45 Gy was given to PTV1 and 50 Gy to PTV2.
3.3. The risk of second cancer inductionWhen an irradiation technique is applied to a largenumber of patients in clinic, it must be take into accountnot only the high dose to the OARs, in order to avoiddeterministic damage, but also the low dose to healthytissue in order to limit the stochastic risk of secondcancer induction. In radiotherapy treatment, high dosesof radiation are used to irradiate the tumor; therefore,the stochastic risk of radiation-induced cancer toneighboring healthy tissues affected by scattered ordirect scattered radiation can assume non-negligiblevalues. Looking at the results of our study, it is evidentthe advantage of the IMRT technique compared to FIF inthe breast irradiation: the same dose coverage of thetarget but a better conformation of it and a spare oforgans at risk from high dose. However, the volumes ofOARs affected by low doses are larger with IMRT. Thiscan be observed in Figure 6 where the dose distributionsobtained with 5F-IMRT and FIF plans in the same CTslice are reported. To allow a better detail of the imagesthe low doses range (0-200 cGy) has been emphasized.The breast tissue is very sensitive to radiation, especiallyfor young women, thus, to find an alternative techniqueto the FIF to be used clinically, we also evaluated thesecondary cancer risk to contralateral breast due toradiation.In our plans the mean secondary dose per 50 Gytreatment dose to this organ was less than 1 Gy: 0.55,0.66, 0.58 and 0.73 Gy, respectively for FIF, H-IMRT,4F-IMRT and 5F-IMRT plans. However, the dosedistribution was highly inhomogeneous as shown, asexample, in Figure 7 for two techniques used in thiswork, where a small part of its volume may receive 5 Gy
or more. We calculated the risk of developing a solidsecond cancer after the radiotherapy using BEIR(Biological Effects of Ionizing Radiation) VII Phase 2models.15,16 The EAR at low dose per 10,000persons-years was evaluated through the organequivalent dose (OED) for the linear model based on thedifferential DVHs.17,18 The EAR is the additional riskabove the background absolute risk (in the absence ofexposure), while OED, for any inhomogenous dosedistribution in an organ, is the dose in Sv, which, whendistributed uniformly across the organ, causes the sameradiation induced cancer incidence. OED values are ageindependent and can be used to compare differenttreatment plans with regard to the organ- andplan-specific secondary cancer induction rate.EAR= EAR0 · OED (per 10,000 persons-years per Gy)
 , 1 ( )T linear i i
iT
OED DVH D DV 
where, DVH (Di) is the volume of the voxel i of organ Treceiving the dose Di and VT is the total organ volume.EAR0 (per 10,000 persons-years per Gy) is the excessabsolute risk at low doses. For breast cancer inductionin females at low doses EAR0 = 3.7 cases per 10,000persons-years per Gy at age of 70 years after exposure atage of 50 years.19Analyzing the DVH data we calculated the EAR values incontralateral breast for all the plans. The results areshowed in Table 4.
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Figure 6: Dose distribution in a transverse plane of the patient due to FIF technique (a) and 5F-IMRT (b).
Figure 7: Dose distribution to the contralateral breast in a transverse plane due to FIF technique (a) and 5F-IMRT (b).As expected, the associated risk is higher in IMRT plansrespect to FIF mainly due to multiple beam angles usedand to scatter dose. The highest value is in the 4F-IMRTplan and not in 5F-IMRT because in the latter the addedanterior beam discharge the dose to the contralateralbreast, but the penalty is an increased dose to the heartand lungs as shown in Figure 6b). Thus, in the case ofyounger patients (<45 years) the 4F-IMRT and 5F-IMRTtechniques should be avoided as they increase the risk ofradio-induced cancer to the breast the first and to heartand lungs the second.
4. ConclusionThe IMRT step and shot technique was implemented inour hospital for those cases in which the standardtangential fields technique or its variant field-in-field,not allowed to obtain good conformation and uniformityof the dose to the targets or sparing of OARs.In this study we investigated three different IMRTtechniques for 11 patients, in terms of delivered dose totargets (PTV breast and PTV boost) and estimated risksof secondary cancer for normal organs. The results werecompared to those obtained with the FIF. We found thatall the techniques achieved approximately the samecoverage of the two targets, but the three IMRT providedan improved conformation. The homogeneity was betterwith IMRT for PTV1 but for PTV2 it was better with the
FIF. All the three IMRT techniques reduced volumes ofthe OARs, as lungs, heart and contralateral breast, whichreceived doses greater than about 15 Gy, but the lowdose (less than about 15 Gy) to the same normal tissues,was increased. Respect to FIF, the larger volumeirradiated to low dose increased the risk of radiationinduced cancer, so these treatments should not be usedextensively, but limited only to those cases in which3DCRT techniques are unable to achieve optimal results.Regarding the treatment delivery time of the IMRTtechniques it was not too longer than the field-in-field(20 min vs. 15 min) but the pre-treatment steps(contouring of organs, planning and pre-treatmentverification) were time expensive for physicist andphysician staff, a further reason to reduce theapplication of these techniques only to selected cases.
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